Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look at the developing treatment landscape for resistant hypertension, including Baxdrostat and Ocedurenone

Ticker(s): CINC, KBP Biosciences

Who's the expert?

Institution: VA Medical Center

received his medical degree from Government Medical College Patiala and has been in practice for 36 years specializing in Endocrinology and Diabetes & Metabolism
manages treatment for 75 patients with resistant hypertension
familiar with Baxdrostat (CIN-107) and KBP-5074 (Ocedurenone)

Interview Goal

Discussing the potential of Baxdrostat (CIN-107) in resistant hypertension and the BrigHtn and HALO phase 2 trials and KBP-5074 (Ocedurenone) for CKD patients with resistant hypertension based on the results of the Phase 2b BLOCK-CKD trial

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.